UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, LAVA, or Company), a clinical-stage immuno-oncology company focused on...
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from...
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, LAVA, or Company), a clinical-stage immuno-oncology company focused on...
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and...
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody„¢...
Lava Therapeutics said Tuesday that it cut 36% of its staff after the biotech stopped all work on a therapy looking to go after CD1d-expressing hematological tumors.